全文获取类型
收费全文 | 72785篇 |
免费 | 4898篇 |
国内免费 | 788篇 |
专业分类
耳鼻咽喉 | 321篇 |
儿科学 | 1300篇 |
妇产科学 | 1088篇 |
基础医学 | 2858篇 |
口腔科学 | 1129篇 |
临床医学 | 13608篇 |
内科学 | 6674篇 |
皮肤病学 | 483篇 |
神经病学 | 2213篇 |
特种医学 | 945篇 |
外国民族医学 | 1篇 |
外科学 | 6343篇 |
综合类 | 11984篇 |
现状与发展 | 6篇 |
一般理论 | 12篇 |
预防医学 | 16411篇 |
眼科学 | 418篇 |
药学 | 6267篇 |
175篇 | |
中国医学 | 4859篇 |
肿瘤学 | 1376篇 |
出版年
2024年 | 98篇 |
2023年 | 1173篇 |
2022年 | 1822篇 |
2021年 | 2983篇 |
2020年 | 3647篇 |
2019年 | 2923篇 |
2018年 | 2674篇 |
2017年 | 2517篇 |
2016年 | 2546篇 |
2015年 | 2600篇 |
2014年 | 6188篇 |
2013年 | 5667篇 |
2012年 | 4988篇 |
2011年 | 5408篇 |
2010年 | 5137篇 |
2009年 | 3433篇 |
2008年 | 3343篇 |
2007年 | 3212篇 |
2006年 | 2866篇 |
2005年 | 2158篇 |
2004年 | 1745篇 |
2003年 | 1557篇 |
2002年 | 1016篇 |
2001年 | 877篇 |
2000年 | 719篇 |
1999年 | 586篇 |
1998年 | 489篇 |
1997年 | 365篇 |
1996年 | 308篇 |
1995年 | 251篇 |
1994年 | 231篇 |
1993年 | 192篇 |
1992年 | 143篇 |
1991年 | 137篇 |
1990年 | 88篇 |
1989年 | 66篇 |
1988年 | 72篇 |
1985年 | 434篇 |
1984年 | 482篇 |
1983年 | 346篇 |
1982年 | 369篇 |
1981年 | 408篇 |
1980年 | 352篇 |
1979年 | 355篇 |
1978年 | 322篇 |
1977年 | 194篇 |
1976年 | 264篇 |
1975年 | 235篇 |
1974年 | 186篇 |
1973年 | 197篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
2.
目的 了解我国老年人中医证候分布特征,为中医药辨治老年人提供参考依据。方法 系统检索中国知识基础设施(CNKI)、中文科技期刊数据库(CCD)、万方数据资源系统数据库(CSPD),纳入研究对象为老年人的临床流行病学调查研究文献,对其调查目的、调查疾病及调查结果等进行描述统计。结果 ①最终纳入168篇文献,其中2010至2020年之间发表138篇(82.14%);调查地区涵盖全国28个省市自治区,共纳入43948例老年人,累计覆盖340个研究中心;②主要研究结果显示,老年人中医证候阴虚阳亢证(10.05%)>血瘀证(9.5%)>痰浊(湿)证(8.91%)>阴阳两虚证(4.98%)>痰瘀互结证(4.96%);单元证分布阴虚证(14.70%)>痰证(11.22%)>气虚证(7.15%)>肾虚证(4.72%)>血瘀证(4.18%);涉及病变脏腑肾>肝>脾>肺>心。结论 根据统计结果,可以看出老年人证候分布虚证多于实证,虚证中又以阴虚证、气虚证最为多见,实证常见血瘀证、痰浊(湿)证等,且多见痰瘀互结证;老年人五脏皆损,其中又以肾、肝、脾功能失调最为突出。 相似文献
3.
目的 建立蒙药绿松石的质量标准。方法 收集不同产地绿松石,共10批。观察绿松石样品和粉末的性状并进行理化鉴别;按2020年版《中国药典》(四部)通则方法测定绿松石样品中水分、浸出物含量;采用原子吸收光谱法测定绿松石样品铜元素含量。结果 绿松石为不规则、周围带有黑石的块状物,表面蓝绿色,体重,质硬脆,难砸碎,断面呈贝壳状,蜡样光泽,粉末呈灰绿色,无臭,味淡;理化鉴别结果显示,呈铜盐反应;10批次样品中水分含量为0.41%-3.94%(SD=1.37%),浸出物含量为0.21%-0.81%(SD=0.21%),铜元素含量为3.03%-4.63%(SD=0.63%)。结论 初步拟定绿松石中水分含量不得超多5.0%、浸出物含量不得低于0.10%,铜元素含量应为2.60%-4.84%,制定的标准可用于蒙药材绿松石的质量控制。 相似文献
4.
5.
6.
7.
Timothy J. Cordingley Mark A.G. Wilson Kathryn M. Weston 《Health & social care in the community》2022,30(1):353-359
Vaccination is a vital health care initiative to prevent individual and population infection. To increase vaccination rates the federal government implemented the ‘No Jab, No Pay’ policy, where eligibility for several government benefits required children to be fully vaccinated by removing ‘conscientious objections’ and expanding the age range of children whose families receive benefits. This study assesses the impact of this policy at a local area within a single medical practice community in NSW, Australia. A retrospective clinical audit was performed between 2012 and 2017 on a single general practice's vaccination records for children ≤19 years. Catch-up vaccinations were assessed based on age at vaccination. Incidence of catch-up vaccinations was assessed for each of four years before and two years after the implementation of the ‘No Jab, No Pay’ policy in January 2016, along with the age of children and vaccination(s) given. Catch-up vaccinations were assessed temporally either side of implementation of ‘No Jab, No Pay’. Comparing the average annual vaccination catch-up incidence rate of 6.2% pre-implementation (2012–2015), there was an increase to 9.2% in 2016 (p < .001) and 7.8% in 2017 (p = .027). Secondary outcome measurement of catch-up vaccination incidence rates before (2012–2015) and after (2016–2017) ‘No Jab, No Pay’ implementation showed statistically significant increases for children aged 8–11 years (3.2%–5.6%, p = .038), 12–15 years (7.5%–14.7%, p < .001) and 16–19 years (3.3%–10.2%, p < .001) along with a statistically significant reduction in children aged 1–3 years (11.4%–6.2%, p = .015). Also, catch-up rates for DTPa significantly increased after program implementation. This study demonstrates that the Australian federal government vaccination policy ‘No Jab, No Pay’ was coincident with an increase in catch-up vaccinations within a rural NSW community served by one medical practice, especially for older children. 相似文献
8.
《Journal of Radiology Nursing》2022,41(2):123-128
ObjectiveThe objective of this study was to reduce errors in a pathologic specimen with the help of a protocol systematizing the pathology specimen management process in the operating room.Materials and methodThis quasi-experimental study was carried out in the operating room unit of a research and training hospital. A protocol systematizing the process of specimen management in secure surgical pathology and prepared in light of the current literature was used as an intervention, and the effectiveness of the protocol was tested.ResultsIt was determined that the rate of adverse events decreased from .3226% (68 of 21,078) to .032% (6 of 18,706) after the protocol systematizing the surgical pathology specimen management process prepared by the researchers, and the protocol was found to be effective by 90% (P = .03).ConclusionBased on the data obtained in this study, we recommend the use of a pathologic specimen management protocol in the operating room. 相似文献
9.
10.
Michael Staehler Peter J. Goebell Lothar Müller Till-Oliver Emde Natalie Wetzel Lisa Kruggel Martina Jänicke Norbert Marschner the RCC-Registry Group 《International journal of cancer. Journal international du cancer》2020,146(5):1307-1315
Non-clear cell renal cell carcinoma is a very rare malignancy that includes several histological subtypes. Each subtype may need to be addressed separately regarding prognosis and treatment; however, no Phase III clinical trial data exist. Thus, treatment recommendations for patients with non-clear cell metastatic RCC (mRCC) remain unclear. We present first prospective data on choice of first- and second-line treatment in routine practice and outcome of patients with papillary mRCC. From the prospective German clinical cohort study (RCC-Registry), 99 patients with papillary mRCC treated with systemic first-line therapy between December 2007 and May 2017 were included. Prospectively enrolled patients who had started first-line treatment until May 15, 2016, were included into the outcome analyses (n = 82). Treatment was similar to therapies used for clear cell mRCC and consisted of tyrosine kinase inhibitors, mechanistic target of rapamycin inhibitors and recently checkpoint inhibitors. Median progression-free survival from start of first-line treatment was 5.4 months (95% confidence interval [CI], 4.1–9.2) and median overall survival was 12.0 months (95% CI, 8.1–20.0). At data cutoff, 73% of the patients died, 6% were still observed, 12% were lost to follow-up, and 9% were alive at the end of the individual 3-year observation period. Despite the lack of prospective Phase III evidence in patients with papillary mRCC, our real-world data reveal effectiveness of systemic clear cell mRCC therapy in papillary mRCC. The prognosis seems to be inferior for papillary compared to clear cell mRCC. Further studies are needed to identify drivers of effectiveness of systemic therapy for papillary mRCC. 相似文献